Cargando…

Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality

The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global health crisis. Currently, a number of risk factors have been identified to have a potential impact on increasing the morbidity of C...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jin-jin, Dong, Xiang, Liu, Guang-hui, Gao, Ya-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767775/
https://www.ncbi.nlm.nih.gov/pubmed/35044620
http://dx.doi.org/10.1007/s12016-022-08921-5
_version_ 1784634803688046592
author Zhang, Jin-jin
Dong, Xiang
Liu, Guang-hui
Gao, Ya-dong
author_facet Zhang, Jin-jin
Dong, Xiang
Liu, Guang-hui
Gao, Ya-dong
author_sort Zhang, Jin-jin
collection PubMed
description The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global health crisis. Currently, a number of risk factors have been identified to have a potential impact on increasing the morbidity of COVID-19 in adults, including old age, male sex, pre-existing comorbidities, and racial/ethnic disparities. In addition to these factors, changes in laboratory indices and pro-inflammatory cytokines, as well as possible complications, could indicate the progression of COVID-19 into a severe and critical stage. Children predominantly suffer from mild illnesses due to COVID-19. Similar to adults, the main risk factors in pediatric patients include age and pre-existing comorbidities. In contrast, supplementation with a healthy diet and sufficient nutrition, COVID-19 vaccination, and atopic conditions may act as protective factors against the infection of SARS-CoV-2. COVID-19 vaccination not only protects vulnerable individuals from SARS-CoV-2 infection, more importantly, it may also reduce the development of severe disease and death due to COVID-19. Currently used therapies for COVID-19 are off-label and empiric, and their impacts on the severity and mortality of COVID-19 are still unclear. The interaction between asthma and COVID-19 may be bidirectional and needs to be clarified in more studies. In this review, we highlight the clinical evidence supporting the rationale for the risk and protective factors for the morbidity, severity, and mortality of COVID-19.
format Online
Article
Text
id pubmed-8767775
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87677752022-01-19 Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality Zhang, Jin-jin Dong, Xiang Liu, Guang-hui Gao, Ya-dong Clin Rev Allergy Immunol Article The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global health crisis. Currently, a number of risk factors have been identified to have a potential impact on increasing the morbidity of COVID-19 in adults, including old age, male sex, pre-existing comorbidities, and racial/ethnic disparities. In addition to these factors, changes in laboratory indices and pro-inflammatory cytokines, as well as possible complications, could indicate the progression of COVID-19 into a severe and critical stage. Children predominantly suffer from mild illnesses due to COVID-19. Similar to adults, the main risk factors in pediatric patients include age and pre-existing comorbidities. In contrast, supplementation with a healthy diet and sufficient nutrition, COVID-19 vaccination, and atopic conditions may act as protective factors against the infection of SARS-CoV-2. COVID-19 vaccination not only protects vulnerable individuals from SARS-CoV-2 infection, more importantly, it may also reduce the development of severe disease and death due to COVID-19. Currently used therapies for COVID-19 are off-label and empiric, and their impacts on the severity and mortality of COVID-19 are still unclear. The interaction between asthma and COVID-19 may be bidirectional and needs to be clarified in more studies. In this review, we highlight the clinical evidence supporting the rationale for the risk and protective factors for the morbidity, severity, and mortality of COVID-19. Springer US 2022-01-19 2023 /pmc/articles/PMC8767775/ /pubmed/35044620 http://dx.doi.org/10.1007/s12016-022-08921-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Zhang, Jin-jin
Dong, Xiang
Liu, Guang-hui
Gao, Ya-dong
Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title_full Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title_fullStr Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title_full_unstemmed Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title_short Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality
title_sort risk and protective factors for covid-19 morbidity, severity, and mortality
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767775/
https://www.ncbi.nlm.nih.gov/pubmed/35044620
http://dx.doi.org/10.1007/s12016-022-08921-5
work_keys_str_mv AT zhangjinjin riskandprotectivefactorsforcovid19morbidityseverityandmortality
AT dongxiang riskandprotectivefactorsforcovid19morbidityseverityandmortality
AT liuguanghui riskandprotectivefactorsforcovid19morbidityseverityandmortality
AT gaoyadong riskandprotectivefactorsforcovid19morbidityseverityandmortality